Hasil Pencarian  ::  Simpan CSV :: Kembali

"Osteoartritis merupakan salah satu penyakit utama penyebab disabilitas. Degradasi tulang rawan pada osteoartritis sulit diatasi karena kemampuan regenerasi tulang rawan yang terbatas. Extracellular vesicles (EVs) dari mesenchymal stem cells (MSCs) memiliki potensi sebagai terapi regeneratif untuk osteoartritis. Regenerasi tulang rawan dapat dianalisis secara histologi menggunakan sistem skor. Analisis molekuler juga dapat dilakukan, misalnya pada salah satu jalur persinyalan yang berperan dalam terjadinya osteoartritis, yaitu jalur persinyalan Wnt. Jalur persinyalan Wnt terdiri dari jalur persinyalan kanonikal dengan aktivator utama WNT3A dan jalur persinyalan nonkanonikal dengan aktivator WNT5A. Belum terdapat penelitian terkait efek pemberian EVs adipose-derived MSCs (AD-MSCs) pada domba model osteoartritis hingga saat ini. Penelitian ini dilakukan untuk mengetahui tingkat regenerasi tulang rawan domba model osteoartritis yang telah diinjeksikan EVs AD-MSCs sebanyak tiga kali setelah induksi osteoartritis berdasarkan sistem skor Modified O’Driscoll dan mengetahui dampak pemberian EVs AD-MSCs pada domba model osteoartritis terhadap ekspresi gen WNT3A dan WNT5A. Tulang rawan model osteoartritis domba diberi injeksi EVs AD-MSCs tiga kali sebagai perlakuan dan injeksi NaCl sebagai kontrol. Hasil pemberian EVs AD-MSCs dianalisis secara histologi menggunakan sistem skor Modified O’Driscoll. Ekspresi gen relatif WNT3A dan WNT5A dianalisis menggunakan qRT-PCR. Hasil penelitian menunjukkan bahwa injeksi EVs AD-MSCs berhasil menyebabkan perbaikan pada tulang rawan model osteoartritis domba. Ekspresi WNT3A memiliki kecenderungan meningkat, sedangkan ekspresi WNT5A memiliki kecenderungan menurun setelah injeksi EVs AD-MSCs. Uji statistik untuk skor Modified O’Driscoll, serta ekspresi gen relatif WNT3A dan WNT5A tidak menunjukkan perbedaan nyata yang disebabkan keterbatasan penelitian ini, yaitu jumlah sampel yang kecil. Berdasarkan hasil penelitian ini, EVs AD-MSCs memiliki potensi untuk regenerasi tulang rawan.......Osteoarthritis is one of the main causes for disability. Cartilage degradation in osteoarthritis is difficult to overcome due to limited regeneration ability of cartilage. Mesenchymal stem cells (MSCs) extracellular vesicles (EVs) has potential as regenerative therapy for osteoarthritis. Cartilage regeneration can be assessed histologically using scoring systems. Molecular analysis can also be done, such as in one of signaling pathways involved in osteoarthritis, Wnt signaling pathway. This signaling pathway consists of canonical signaling pathway with its main activator, WNT3A, and noncanonical signaling pathway with its activator, WNT5A. Currently, there is no study regarding adipose-derived MSCs (AD-MSCs) EVs effects on osteoarthritic sheep cartilage model. This study aims to know cartilage regeneration degree on osteoarthritic sheep cartilage model after three injections of AD-MSCs EVs after osteoarthritis induction based on Modified O’Driscoll scoring system and to know AD-MSCs EVs effect on WNT3A and WNT5A gene expression in osteoarthritic sheep. Osteoarthritic sheep cartilage model were given three injections of AD-MSCs EVs as treatment and NaCl as control. The result of AD-MSCs EVs injections was assessed histologically using Modified O’Driscoll scoring system. Relative gene expression of WNT3A and WNT5A were assessed using qRT-PCR. This study shows that AD-MSCs EVs injections resulted in repair of osteoarthritic sheep cartilage model. Expression of WNT3A showed tendency to increase, whereas expression of WNT5A showed tendency to decrease after AD-MSCs EVs injections. Statistical analysis for Modified O’Driscoll score as well as WNT3A and WNT5A relative gene expression showed no significant difference due to limitation of this study which is small sample size. Based on these results, AD-MSCs EVs shows potential to regenerate cartilage."

"Latar Belakang: Fibrosis hati disebabkan cedera hati kronis akan menjadi sirosis. Vesikel ekstraseluler (VE) dan Hepatocyte Growth Factor (HGF) banyak dipelajari sebagai terapi fibrosis dan regenerasi hati. Penelitian ini memanfaatkan kombinasi VE dan recombinant human-HGF ( rh-HGF) sebagai terapi alternatif fibrosis hati pada model tikus ligasi duktus bilier (LDB).Metode: Sebelas tikus Sprague Dawley (SD) menjalani LDB, 5 tikus kontrol dan 6 tikus mendapat perlakuan injeksi VE 150 uL dan rh-HGF 0,1 mg intravena sejak 3 minggu pasca LDB, selama 7 hari. Satu tikus kontrol diterminasi 3 minggu pasca LDB sebagai data dasar. Tikus-tikus kelompok kontrol dan perlakuan diterminasi pada 1 hari dan 2 minggu setelah injeksi terakhir. Dilakukan penilaian skor Laennec hati serta kadar HGF, alanine aminotransferase (ALT) dan aspartate aminotransferase (AST).Hasil: Histopatologi 3 minggu pasca LDB menunjukkan skor Laennec 2. Skor fibrosis kelompok kontrol (KK) dan kelompok perlakuan (KP) 1 minggu dan 2 minggu pasca injeksi VE dan rh-HGF seluruhnya dengan skor 2. Kadar HGF pada KP lebih rendah secara signifikan dibandingkan dengan KK 1 hari pasca injeksi terakhir (1,35+0,06 vs 1,53+0,06; p<0,001), semakin menurun setelah 2 minggu pasca injeksi terakhir namun tidak bermakna secara statistik 0,83 (0,73-0,84) vs 0,76 (0,73-0,80) p=0,248). Kadar AST 1 hari pasca injeksi terakhir; KK 1,66+0,05 KP 0,91+0,12 debgan p = 0,001. Setelah 2 minggu pasca injeksi; kadar AST pada kedua kelompok menurun 1,12 (1,11-1,22) vs (0,96+0,03); p=0,021). Kadar ALT pada kelompok perlakuan lebih rendah secara signifikan pada 1 hari pasca injeksi dan 2 minggu pasca injeksi dengan nilai p<0,001 dan 0,033a......Background: Fibrosis of the liver due to a chronic liver injury will become cirrhosis at the end-stage. The Extracellular Vesicles (EV) and hepatocyte growth factor (HGF) are recently learned as much as fibrosis and liver regeneration therapy. This study aims to know the result of using a combination of EV and recombinant human HGF (rh-HGF) as an alternative therapy due to liver fibrosis on the rat bile duct ligation (BDL) model.Methods: Eleven BDL Sprague Dawley (SD) were divided into two groups, five mice as the untreated control group and six mice as the treatment group was getting an EV 150 ul and rh-hgf 0.1 mg intravenous injection three weeks after BDL, for seven days. One control rat is expanded three weeks after BDL as baseline data. The control and treatment group mice were projected at day one and two weeks after the final injection. This study was assessed from liver fibrosis by using Laennec score, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and Hepatocyte Growth Factor (HGF) level. Results: Scoring of histopathology by using the Laennec score at 3 weeks after BDL was 2. Meanwhile scoring of fibrosis of the control group and treatment group at 1 week and 2 weeks after ve and rh-hgf injection were 2. HGF level of the treatment group was lower significantly than control group at day 1 after last injection (1,35+0,06 vs 1,53+0,06; p<0,001), and within 2 weeks, the number of HGF levels decreased but statistically insignificant; 0,83 (0,73-0,84) vs 0,76 (0,73-0,80) p=0,248). AST level at day 1 after last injection; control group vs treatment group ;1,66+0,05 vs 0,91+0,12, p value = 0,001. 2 weeks after injection; AST level for both group were become lower 1,12 (1,11-1,22) vs (0,96+0,03); p=0,021), and ALT level on treatment group was significantly lower at day 1 and 2 weeks after injection with p value <0,001 and 0, 033a"